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BACKGROUND
• Erythrocytosis (high hemoglobin) most common-

ly results from secondary causes such as hypoxia (Box 1), but it may also be caused by a primary, underlying condition known as polycythemia
vera (PV).

• PV is a rare cancer of the bone marrow which

causes an increased production of red blood
cells and may lead to complications such as clotting, itchiness from water, an enlarged spleen,
and possible transformation into acute leukemia.

• To distinguish PV from secondary erythrocyto-

sis, a molecular test can be performed which sequences the Janus kinase 2 (JAK2) gene and
looks for a mutation which is present in 95% of
PV patients.

• At LHSC, an increase in molecular testing for pa-

tients with suspected PV and a decrease in the
number of positive tests suggests that this test
is being overused.

• The objective of our study was to develop a sim-

ple rule to help physicians distinguish between
PV and other secondary causes of erythrocytosis in order to reduce indiscriminate ordering of
JAK2 mutation testing.

Box 1. Common causes of erythrocytosis.

• Primary
o Polycythemia vera (PV)
• Secondary
o Hypoxia (e.g. smoking, chronic obstructive pulmonary disorder, obstructive sleep apnea)

o Medications (e.g. testosterone, sodium/glucose
cotransporter 2 [SGLT2] inhibitors)

o Erythropoietin-secreting tumours (e.g. renal cell
carcinoma, hepatocellular carcinoma)
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METHODS
Data Collection
• Between January 2018 and May 2021, patients

with hemoglobin levels ≥ 160 g/L (women) or
165 g/L (men) who underwent JAK2 mutation
testing at LHSC using the next-generation sequencing (NGS)-based Oncomine Myeloid Research Assay (ThermoFisher Scientific, MA,
USA) were identified.

• Age, sex, and complete blood count parameters

were extracted from their electronic records.

• Patients were divided into two cohorts by year:
o Derivation cohort (2018–2019)
o Validation cohort (2020–2021)

Derivation of the Prediction Rule

RESULTS
Table 1. Characteristics of the derivation and validation cohorts.
Derivation cohort Validation cohort
(n = 308)
(n = 223)

Characteristic
Age, mean (SD)

58 (14)

59 (14)

229 (74)

161 (73)

9.1 (4.1)

9.1 (3.3)

5.87 (0.66)

5.91 (0.57)

Hemoglobin, mean (SD) (g/L)

177 (12)

177 (11)

Hematocrit, mean (SD) (L/L)

0.53 (0.04)

0.53 (0.04)

Platelets, mean (SD) (× 109/L)

269 (162)

278 (168)

Neutrophils, mean (SD) (× 109/L)

5.9 (4.3)

5.9 (2.4)

Male sex, number (%)
Leukocytes, mean (SD) (× 109/L)
Erythrocytes, mean (SD) (× 1012/L)

Hemoglobin ≥ 160 g/L (women) or 165 g/L (men)

• In the derivation cohort, potentially significant

predictors of JAK2 positivity were identified, dichotomized using receiver operating characteristic curves, and modelled using multivariable
stepwise logistic regression analysis.

• The final model was evaluated using the Hosmer

-Lemeshow test and pseudo-R2 measures, and
internally validated using logistic regression and
non-parametric bootstrapping.

Validation of the Prediction Rule
• The rule was applied to both cohorts to validate

and assess the rule’s performance.

• Sensitivity: the percentage of patients with a

JAK2 mutation who are correctly identified by
the rule.

• Specificity: the percentage of patients without a

JAK2 mutation who are correctly identified by
the rule.

• Positive predictive value (PPV): the probability

that the prediction rule correctly identifies the
presence of a JAK2 mutation.

• Negative predictive value (NPV): the probability

that the prediction rule correctly identifies the
absence of a JAK2 mutation.

Red blood cell count > 6.17 × 1012/L
or
Platelet count > 308 × 109/L
yes
Test for JAK2 mutations

no

Table 2. JAK2 prediction rule performance
for each of the cohorts. PPV, positive predictive value; NPV, negative predictive value.
Performance
measure

Derivation
cohort

Validation
cohort

Sensitivity

86.8%

100%

Specificity

68.9%

62.1%

PPV

28.2%

20.6%

NPV

97.4%

100%

Table 3. Contingency table for the JAK2 prediction rule. Bolded numbers in purple indicate the number of tests which could have
been avoided if this prediction rule was retrospectively applied.
Cohort

Derivation

Do not test for JAK2 mutations

Figure 1. Flowchart illustrating the prediction rule that was generated to
help guide JAK2 mutation testing. The rule uses the red blood cell and
platelet counts, both of which are routinely and easily measured as part
of a complete blood count.

Validation

Prediction
rule

JAK2 mutation
Positive

Negative

Test

33
(10.7%)

84
(27.2%)

Do not
test

5
(1.6%)

186
(60.4%)

Test

20
(9.0%)

77
(34.5%)

Do not
test

0
(0.0%)

126
(56.5%)

CONCLUSION
• In the derivation cohort, the prediction rule accurately identified 86.8% of JAK2-positive patients while

correctly screening out 97.4% of patients as being JAK2-negative (Table 2). Similarly, in the validation cohort, the prediction rule accurately identified 100% of JAK2-positive patients while correctly screening out
100% of patients as being JAK2-negative (Table 2).

• Over 300 tests between January 2018 and May 2021 could have been avoided by using this prediction

rule, a reduction of approximately 60% (Table 3).

• In summary, we developed and validated a simple rule to predict the likelihood of a JAK2 mutation in pa-

tients with elevated hemoglobin levels which could improve resource allocation and reduce unnecessary
testing.

